Federal contract award
75N91022F00001
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS-- TARGETING THE PARP PATHWAY FOR THE PREVENTION OF BREAST CANCER
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | 75N91019D00021 |
| Set-aside | Not reported |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $1.1M |
| Current contract value | $1.1M |
| Potential contract value / ceiling | $1.1M |
| Start date | Jun 1, 2022 |
| Current end date | May 31, 2027 |
| Potential end date | May 31, 2027 |
| Latest award activity | Apr 28, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Apr 28, 2026 | P00005 | $0 | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: TARGETING THE PARP PATHWAY FOR THE PREVENTION OF BREAST CANCER (2022 E-01) |
| Mar 18, 2025 | P00004 | $0 | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: TARGETING THE PARP PATHWAY FOR THE PREVENTION OF BREAST CANCER (2022 E-01) |
| Mar 11, 2025 | P00003 | $0 | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: TARGETING THE PARP PATHWAY FOR THE PREVENTION OF BREAST CANCER (2022 E-01) |
| May 23, 2023 | P00002 | $0 | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: TARGETING THE PARP PATHWAY FOR THE PREVENTION OF BREAST CANCER (2022 E-01) |
| Jun 30, 2022 | P00001 | $0 | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS TASK ORDER TITLE: TARGETING THE PARP PATHWAY FOR THE PREVENTION OF BREAST CANCER (2022 E-01) |
| May 24, 2022 | 0 | $1.1M | PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS-- TARGETING THE PARP PATHWAY FOR THE PREVENTION OF BREAST CANCER |
Estimated positioning window
Nov 1, 2026 – Jan 30, 2027
85/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 85/100. Available recorded signals: 80 points.
- Contract end 2027-05-31 (211 days from calculation)
- +35 points
- 48 historical awards in this buyer and category group
- +15 points
- 6 recorded award transactions
- +10 points
- Latest award action: 2026-04-28
- +5 points
- Parent award identifier recorded
- +5 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.